Novavax Inc vs Teradata Corporation Common Stock — how do they compare? Novavax Inc trades at $12.49 (market cap $2.11B), while Teradata Corporation Common Stock trades at $29.6 (market cap $2.83B). The key difference: Teradata Corporation Common Stock is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Teradata Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Teradata Corporation Common Stock for 0 Days on average.
| NVAX | TDC | |
|---|---|---|
Market Cap | $2.11B | $2.83B |
Volume | 8,376,831 | 1,343,944 |
Sector | Health | Technology |
52-Week High | $12.82 | $37.88 |
52-Week Low | $6.22 | $20.71 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $1.69B | $2.52B |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.64, down slightly by 0.16% on the day. The stock shows a bullish technical signal with strong moving average and oscillator support. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of -$0.32 surpassing the -$0.38 estimate. The company is transitioning its business model toward a partnership-driven approach centered on its Matrix-M adjuvant technology, with recent regulatory approvals for its updated COVID-19 vaccine in major markets.
The outlook is mixed with strong analyst buy ratings (73.9%) and recent business developments providing catalysts, but significant financial risks remain including negative cash flows, high debt levels, and inconsistent profitability. Investment opportunity exists in the partnership strategy execution, while risks include execution challenges and competitive pressures in the vaccine market.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Teradata Corporation develops a hybrid cloud analytics and data platform, including its Teradata Vantage and VantageCloud products, that helps enterprises manage and analyze data across cloud, on-premises, and hybrid environments. It serves industries including retail, financial services, healthcare, and manufacturing.
Read more on TDC →